SRC Kinase-mediated Signaling Pathways and Targeted Therapies in Breast Cancer

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2022 Dec 29

PMID 36581908

Authors

Juan Luo

Hailin Zou

Yibo Guo

Tongyu Tong

Liping Ye

Chengming Zhu

Liang Deng

Bo Wang

Yihang Pan

Peng Li

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction.

Citing Articles

CYP2A6 suppresses hepatocellular carcinoma via inhibiting SRC/Wnt/β-Catenin pathway.

Liu Y, Feng L, Zhang W, Zhang X, Shao L, Zhao X Acta Pharmacol Sin. 2025; .

PMID: 40069491 DOI: 10.1038/s41401-025-01524-8.

The IGF2BP1 oncogene is a druggable mA-dependent enhancer of YAP1-driven gene expression in ovarian cancer.

Schott A, Simon T, Muller S, Rausch A, Busch B, Glass M NAR Cancer. 2025; 7(1):zcaf006.

PMID: 40008228 PMC: 11850222. DOI: 10.1093/narcan/zcaf006.

Mechanisms of Cancer-Induced Bone Pain.

Wang X, Li L, Wang Y J Pain Res. 2025; 18:315-326.

PMID: 39867539 PMC: 11760761. DOI: 10.2147/JPR.S498466.

A network pharmacology approach to elucidate the anti-inflammatory and antioxidant effects of bitter leaf ( Del.).

Sailah I, Tallei T, Safitri L, Tamala Y, Halimatushadyah E, Ekatanti D Narra J. 2025; 4(3):e1016.

PMID: 39816097 PMC: 11731942. DOI: 10.52225/narra.v4i3.1016.

Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors.

Choi Y, Kim M, Lee Y, Choi M, Shim W, Park M Theranostics. 2025; 15(3):875-893.

PMID: 39776795 PMC: 11700852. DOI: 10.7150/thno.100970.

References

Biscardi J, Maa M, Tice D, Cox M, Leu T, Parsons S . c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999; 274(12):8335-43. DOI: 10.1074/jbc.274.12.8335. View

Poulard C, Treilleux I, Lavergne E, Bouchekioua-Bouzaghou K, Goddard-Leon S, Chabaud S . Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol Med. 2012; 4(11):1200-13. PMC: 3494876. DOI: 10.1002/emmm.201201615. View

Giatromanolaki A, Sivridis E, Fiska A, Koukourakis M . The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol. 2010; 28(3):745-52. DOI: 10.1007/s12032-010-9530-3. View

Ma X, Zhang L, Song J, Nguyen E, Lee R, Rodgers S . Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation. Nat Commun. 2019; 10(1):296. PMC: 6336867. DOI: 10.1038/s41467-018-08154-1. View

Aggelis V, Johnston S . Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs. 2019; 79(17):1849-1866. DOI: 10.1007/s40265-019-01208-8. View

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Rasha F, Sharma M, Pruitt K . Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021; 532:111322. DOI: 10.1016/j.mce.2021.111322. View

Lu Y, Yu Q, Liu J, Zhang J, Wang H, Koul D . Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003; 278(41):40057-66. DOI: 10.1074/jbc.M303621200. View

Galliher A, Schiemann W . Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007; 67(8):3752-8. DOI: 10.1158/0008-5472.CAN-06-3851. View

10.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T . Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 2014; 19(4):348-9. PMC: 3983830. DOI: 10.1634/theoncologist.2014-0021. View

11.

Hebbard L, Cecena G, Golas J, Sawada J, Ellies L, Charbono A . Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene. 2010; 30(3):301-12. PMC: 3000443. DOI: 10.1038/onc.2010.412. View

12.

Alvarez R . Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010; 12 Suppl 2:S1. PMC: 2972555. DOI: 10.1186/bcr2572. View

13.

Peiro G, Ortiz-Martinez F, Gallardo A, Perez-Balaguer A, Sanchez-Paya J, Ponce J . Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer. 2014; 111(4):689-95. PMC: 4134494. DOI: 10.1038/bjc.2014.327. View

14.

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

15.

Jin L, Chun J, Pan C, Alesi G, Li D, Magliocca K . Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene. 2017; 36(27):3797-3806. PMC: 5501759. DOI: 10.1038/onc.2017.6. View

16.

Jiang T, Qiu Y . Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem. 2003; 278(18):15789-93. DOI: 10.1074/jbc.M212525200. View

17.

Mishra Y, Manavathi B . Focal adhesion dynamics in cellular function and disease. Cell Signal. 2021; 85:110046. DOI: 10.1016/j.cellsig.2021.110046. View

18.

Herynk M, Beyer A, Cui Y, Weiss H, Anderson E, Green T . Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther. 2006; 5(12):3023-31. DOI: 10.1158/1535-7163.MCT-06-0394. View

19.

Fan P, Griffith O, Agboke F, Anur P, Zou X, McDaniel R . c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res. 2013; 73(14):4510-20. PMC: 3715569. DOI: 10.1158/0008-5472.CAN-12-4152. View

20.

Myoui A, Nishimura R, Williams P, Hiraga T, Tamura D, Michigami T . C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003; 63(16):5028-33. View